Replies to post #53448 on Innovation Pharmaceuticals Inc (IPIX)

[ridinbulls]

I agree that the only way B achieves the greatest potential value is based on it being "Non-Inferior".

[alwaysdreaming]

"Then the extra benefits of single dose, lower resistance and lower threat of resistance really can multiply the potential"

I agree whole heartedly with your statement here, but to say CTIX's PPS will tank if the above does not come true is pure BS.

Of course that's my opinion, and when I questioned your timing to make such a statement when the PPS is semi tanking.... Well, I wont repeat myself.

[MinnieM]

With lower threat of resistance it would become standard of care even if only equal to in efficacy. The resistance issue is huge.

Single dosage would be quite the bonus.






In Reply to 'noretreat'
I am thinking that to become the standard of care, B needs to be "non-inferior" to daptomycin. Then the extra benefits of single dose, lower resistance and lower threat of resistance really can multiply the potential. I am optimistic about the trial, but it is not without risk.

Wild-I don't think there have been any changes made to B for this trial besides dosage level and frequency...